Inhibition of eNOS Partially Blunts the Beneficial Effects of Nebivolol on Angiotensin II-Induced Signaling in H9c2 Cardiomyoblasts
Open Access
- 10 May 2022
- journal article
- research article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 44 (5) , 2139-2152
Abstract
We have recently illustrated that nebivolol can inhibit angiotensin II (Ang II)-mediated signaling in cardiomyoblasts; however, to date, the detailed mechanism for the beneficial effects of nebivolol has not been studied. Here, we investigated whether the inhibition of NO bioavailability by blocking eNOS (endothelial nitric oxide synthase) using L-NG-nitroarginine methyl ester (L-NAME) would attenuate nebivolol-mediated favorable effects on Ang II-evoked signaling in H9c2 cardiomyoblasts. Our data reveal that the nebivolol-mediated antagonistic effects on Ang II-induced oxidative stress were retreated by concurrent pretreatment with L-NAME and nebivolol. Similarly, the expressions of pro-inflammatory markers TNF-α and iNOS stimulated by Ang II were not decreased with the combination of nebivolol plus L-NAME. In contrast, the nebivolol-induced reduction in the Ang II-triggered mTORC1 pathway and the mRNA levels of hypertrophic markers ANP, BNP, and β-MHC were not reversed with the addition of L-NAME to nebivolol. In compliance with these data, the inhibition of eNOS by L-N⁵-(1-Iminoethyl) ornithine (LNIO) and its upstream regulator AMP-activated kinase (AMPK) with compound C in the presence of nebivolol showed effects similar to those of the L-NAME plus nebivolol combination on Ang II-mediated signaling. Pretreatment with either compound C plus nebivolol or LNIO plus nebivolol showed similar effects to those of the L-NAME plus nebivolol combination on Ang II-mediated signaling. In conclusion, our data indicate that the rise in NO bioavailability caused by nebivolol via the stimulation of AMPK/eNOS signaling is key for its anti-inflammatory and antioxidant properties but not for its antihypertrophic response upon Ang II stimulation.Keywords
Funding Information
- King Abdulaziz City for Science and Technology (12-MED3221-02)
This publication has 37 references indexed in Scilit:
- RAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative ApproachesCardiorenal Medicine, 2012
- Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) ratAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- Nitric oxide inhibits the expression of AT1 receptors in neuronsAmerican Journal of Physiology-Cell Physiology, 2012
- Beta3-Adrenoreceptor Stimulation Ameliorates Myocardial Ischemia-Reperfusion Injury Via Endothelial Nitric Oxide Synthase and Neuronal Nitric Oxide Synthase ActivationJACC, 2011
- Complex Inhibitory Effects of Nitric Oxide on AutophagyMolecular Cell, 2011
- Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular systemJournal of Molecular and Cellular Cardiology, 2010
- Nebivolol Improves Diastolic Dysfunction and Myocardial Remodeling Through Reductions in Oxidative Stress in the Zucker Obese RatHypertension, 2010
- Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the β3-adrenoreceptorJournal of Molecular and Cellular Cardiology, 2009
- MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in miceJournal of Clinical Investigation, 2009
- Nitric Oxide and Peroxynitrite in Health and DiseasePhysiological Reviews, 2007